Altimmune Could Find A Partner For Its Phase 3 Exercise
Portfolio Pulse from
Altimmune is seeking a partner or acquisition to fund its Phase 3 trial for pemvidutide, as its current cash reserves are insufficient. Without a partner, a significant fund raise may be necessary, potentially impacting stock prices.
December 30, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Altimmune needs a partner or acquisition to fund its Phase 3 trial for pemvidutide. Without this, a significant fund raise could negatively impact stock prices.
Altimmune's current cash reserves are insufficient to fund the Phase 3 trial for pemvidutide, requiring 5,000 patients. The company is seeking a partner or acquisition to avoid a significant fund raise, which could dilute shares and negatively impact stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100